Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 15/20 | 0.41 |
| ▸ | CSF1R | P07333 | 2/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.36 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.36 |
| ▸ | MPO | P05164 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1883982 | 0.89 | PIK3CD (0.39) | PIK3CDCSF1RFGFR1FGFR2FGFR3 | |
| SCHEMBL1875477 | 0.80 | PIK3CD (0.59) | PIK3CD | |
| SCHEMBL1883842 | 0.77 | MEN1 (0.41) | PIK3CDFGFR1FGFR2FGFR3 | |
| SCHEMBL716728 | 0.76 | PIK3CD (0.57) | PIK3CD | |
| SCHEMBL714331 | 0.74 | PIK3CD (0.59) | PIK3CD | |
| SCHEMBL1888178 | 0.72 | PIK3CD (0.45) | PIK3CDMPO | |
| SCHEMBL1882069 | 0.70 | PIK3CD (0.39) | PIK3CDFGFR1FGFR2FGFR3 | |
| SCHEMBL1882072 | 0.70 | PIK3CD (0.39) | PIK3CDFGFR1FGFR2FGFR3 | |
| SCHEMBL715578 | 0.70 | PIK3CD (0.47) | PIK3CDPRMT5 | |
| SCHEMBL1884628 | 0.69 | PIK3CD (0.40) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399483-B2 | Quinoxaline and quinoline derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2013-03-19 | — | — | US | disclosed |
| US-20110105508-A1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA, S.A. (BE) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105508-A1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | PDXK, PDPK1, PIKFYVE | PIK3CD 8/4885CSF1R 2607/4885FGFR1 3795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.